Low-Dose Chemotherapy for Infants with Neuroblastoma
Author Information
Author(s): Rubie H, Coze C, Plantaz D, Munzer C, Defachelles A S, Bergeron C, Thomas C, Chastagner P, Valteau-Couanet D, Michon J, Mosseri V, Hartmann O
Primary Institution: Société Française d'Oncologie Pédiatrique (SFOP)
Hypothesis
Can low-dose chemotherapy improve outcomes for infants with localized unresectable neuroblastoma?
Conclusion
Low-dose chemotherapy is effective in about half of infants with unresectable neuroblastoma, allowing safe surgical resection and reducing long-term side effects.
Supporting Evidence
- Among 39 infants with localized unresectable neuroblastoma, 90% had event-free survival.
- Survival rates were similar to those observed in previous studies with more intensive chemotherapy.
- Only 4 children experienced relapse, all local.
Takeaway
This study shows that giving less intense chemotherapy to babies with a certain type of cancer can help them get better without causing too many side effects.
Methodology
The study included infants under 12 months with localized unresectable neuroblastoma, treated with low-dose cyclophosphamide and vincristine, followed by surgery if the tumor shrank sufficiently.
Potential Biases
Potential selection bias due to the strict eligibility criteria.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
Infants under 12 months with localized unresectable neuroblastoma.
Statistical Information
P-Value
<0.001
Confidence Interval
90±5%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website